Literature DB >> 1967269

HIV-gp120 can block CD4-class II MHC-mediated adhesion.

Y Rosenstein1, S J Burakoff, S H Herrmann.   

Abstract

A possible component of the immune dysfunction associated with infection by HIV is the inhibition of CD4 function resulting from the avid binding of soluble HIV envelope glycoprotein (gp120) to cell surface CD4. We assessed CD4 function by measuring the ability of CD4+ T cells to form conjugates with cell size lipid vesicles, artificial target cells (ATC), bearing the natural ligand for CD4, MHC class II proteins. Conjugate formation was a transient process with the greatest number of specific cell to ATC conjugates found after approximately 30 min of incubation at 37 degrees C. Addition of gp120 specifically blocked conjugates between CD4+ cells and class II ATC in a concentration-dependent manner. These data indicate that T lymphocyte adhesion mediated by CD4 is a dynamic event and that binding of gp120 to CD4 is able to disrupt the normal progression of the interaction between CD4+ T lymphocytes and class II+ APC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967269

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  A gp120 HIV peptide with high similarity to HLA class II beta chains enhances PPD-specific and autoreactive T cell activation.

Authors:  O Pugliese; M Viora; B Camponeschi; P Cordiali Fei; F Caprilli; A Chersi; M Evangelista; A M Di Massimo; V Colizzi
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

2.  Patterns of immune, neuroendocrine, and cardiovascular stress responses in asymptomatic HIV seropositive and seronegative men.

Authors:  K R Starr; M H Antoni; B E Hurwitz; M S Rodriquez; G Ironson; M A Fletcher; M Kumar; R Patarca; S K Lutgendorf; R E Quillian; N G Klimas; N Schneiderman
Journal:  Int J Behav Med       Date:  1996

3.  An idiotypic network model of AIDS immunopathogenesis.

Authors:  G W Hoffmann; T A Kion; M D Grant
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Staphylococcal enterotoxin A and toxic shock syndrome toxin compete with CD4 for human major histocompatibility complex class II binding.

Authors:  S Bavari; R G Ulrich
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

Review 5.  The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.

Authors:  S Bour; R Geleziunas; M A Wainberg
Journal:  Microbiol Rev       Date:  1995-03

6.  A distinct cytoplasmic domain of CD2 regulates ligand avidity and T-cell responsiveness to antigen.

Authors:  W C Hahn; Y Rosenstein; V Calvo; S J Burakoff; B E Bierer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

7.  Superantigen staphylococcal enterotoxin B-induced T-helper cell activation is independent of CD4 molecules and phosphatidylinositol hydrolysis.

Authors:  N Oyaizu; N Chirmule; H Yagura; R Pahwa; R A Good; S Pahwa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

8.  Analysis of the basis of resistance and susceptibility of CD4+ T cells to human immunodeficiency virus (HIV)-gp120 induced anergy.

Authors:  A Faith; R E O'Hehir; M Malkovsky; J R Lamb
Journal:  Immunology       Date:  1992-06       Impact factor: 7.397

9.  Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis.

Authors:  S Sabbaj; M F Para; R J Fass; P W Adams; C G Orosz; C C Whitacre
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

10.  Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis.

Authors:  J F Zagury; J Bernard; A Achour; A Astgen; A Lachgar; L Fall; C Carelli; W Issing; J P Mbika; O Picard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.